Literature DB >> 9601507

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

G Antoine1, F Scheiflinger, F Dorner, F G Falkner.   

Abstract

The complete genomic DNA sequence of the highly attenuated vaccinia strain modified vaccinia Ankara (MVA) was determined. The genome of MVA is 178 kb in length, significantly smaller than that of the vaccinia Copenhagen genome, which is 192 kb. The 193 open reading frames (ORFs) mapped in the MVA genome probably correspond to 177 genes, 25 of which are split and/or have suffered mutations resulting in truncated proteins. The left terminal genomic region of MVA contains four large deletions and one large insertion relative to the Copenhagen strain. In addition, many ORFs in this region are fragmented, leaving only eight genes structurally intact and therefore presumably functional. The inserted DNA codes for a cluster of genes that is also found in the vaccinia WR strain and in cowpox virus and includes a highly fragmented gene homologous to the cowpox virus host range gene, providing further evidence that a cowpox-like virus was the ancestor of vaccinia. Surprisingly, the central conserved region of the genome also contains some fragmented genes, including ORF F5L, encoding a major membrane protein, and ORFs F11L and O1L, encoding proteins of 39.7 and 77.6 kDa, respectively. The right terminal genomic region carries three large deletions all classical poxviral immune evasion genes and all ankyrin-like genes located in this region are fragmented except for those encoding the interleukin-1 beta receptor and the 68-kDa ankyrin-like protein B18R. Thus, the attenuated phenotype of MVA is the result of numerous mutations, particularly affecting the host interactive proteins, including the ankyrin-like genes, but also involving some structural proteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601507     DOI: 10.1006/viro.1998.9123

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  230 in total

1.  Genome-wide analysis of vaccinia virus protein-protein interactions.

Authors:  S McCraith; T Holtzman; B Moss; S Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Poxvirus-induced immunostimulating effects on porcine leukocytes.

Authors:  V Fachinger; T Schlapp; W Strube; N Schmeer; A Saalmüller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

5.  Extensive gene gain associated with adaptive evolution of poxviruses.

Authors:  Aoife McLysaght; Pierre F Baldi; Brandon S Gaut
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

6.  Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome.

Authors:  Chris Upton; Stephanie Slack; Arwen L Hunter; Angelika Ehlers; Rachel L Roper
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.

Authors:  Anton V Cheltsov; Mika Aoyagi; Alexander Aleshin; Eric Chi-Wang Yu; Taylor Gilliland; Dayong Zhai; Andrey A Bobkov; John C Reed; Robert C Liddington; Ruben Abagyan
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

8.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

9.  Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Authors:  Juan Carlos Gallego-Gómez; Cristina Risco; Dolores Rodríguez; Pilar Cabezas; Susana Guerra; José L Carrascosa; Mariano Esteban
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.